# Study of Fluoxetine in Autism

> **NCT00515320** · PHASE3 · COMPLETED · sponsor: **Neuropharm** · enrollment: 158 (actual)

## Conditions studied

- Autistic Disorder

## Interventions

- **DRUG:** Fluoxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00515320
- **Lead sponsor:** Neuropharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2012-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515320, "Study of Fluoxetine in Autism". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00515320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*